FIELD: pharmaceutics.
SUBSTANCE: invention relates to composition presented by formula (I) or its pharmaceutically acceptable salt, where R1 is hydrogen atom; R2 is aromatic ring group defined in claim, R3 is hydrogen or fluorine atom, R4 is hydrogen atom; R5 is oxepanyl group, etc.; R6 is hydrogen atom. Disclosed composition exhibits PDE9-inhibiting action. Therefore, intracerebral proteins concentration increase is possible. PDE9-inhibitory action and cGMP increase leads to improvement of training course and memory development.
EFFECT: composition of formula (I) can be used as therapeutic agent against cognitive dysfunctions accompanying Alzheimer's disease.
19 cl, 1 dwg, 12 tbl, 63 ex
(I)
Title | Year | Author | Number |
---|---|---|---|
SALT OF PYRAZOLOQUINOLINE DERIVATIVE AND CRYSTAL THEREOF | 2014 |
|
RU2655171C2 |
PYRAZOLOPYRIMIDINE DERIVATIVE | 2007 |
|
RU2420530C2 |
PYRAZOLE DERIVATIVE OR ITS PHARMACEUTICALLY ACCEPTABLE SALT | 2016 |
|
RU2687245C1 |
PYRIDINYLPYRAZOLOQUINOLINE COMPOUNDS | 2014 |
|
RU2655172C2 |
LOCAL ANTIMYCOTIC AGENT | 2012 |
|
RU2593990C2 |
CONDENSED AMINOHYDROTHIAZINE DERIVATIVE | 2009 |
|
RU2476431C2 |
BENZIMIDAZOLE DERIVATIVE | 2006 |
|
RU2409573C2 |
PYRAZOLE DERIVATIVES | 2004 |
|
RU2332412C2 |
CYCLOHEXANE DERIVATIVE AND ITS PHARMACEUTICAL USE | 2009 |
|
RU2478621C2 |
NOVEL IMIDAZOOXAZINE COMPOUND OR SALT THEREOF | 2012 |
|
RU2578608C2 |
Authors
Dates
2016-12-20—Published
2012-10-04—Filed